QuaraSense™ is an entirely new technology platform that will measure the signature of infectious bacteria, enabling rapid response and greater chance for stopping an infection. Treatment efficacy may be measured on an ongoing basis.
This will also be the first platform capable of detecting a wide range of infectious microorganisms with one test. QuaraSense™ technology is testing made simple because it samples from the environment in which the infection is suspected. The days of chasing a population of bacteria with a test tube are over.
Save lives, alleviate suffering and improve the world’s food supply.
Humanity has been battling bacteria almost since the beginning of time. Now we have superbugs. Our strategy needs to change.
Superbugs are expected to cost the global economy $100 trillion in health care and lost productivity by 2050 (as per the International Federation of Pharmaceutical Manufacturers & Associations, Nov 2018).
Current methods for detection of bacteria are inadequate — this leads to billions in food production losses.
We overuse antibiotics, in part because we do not detect infections early enough and lack timely feedback on a drug’s effectiveness.
Antibiotic-resistant strains of bacteria are present in humans, animals and fish.
Markets for Quara’s Sensors for Life
Early warnings of bacteria outbreak will reduce the overuse of antibiotics.
QuaraSense™ will help reduce the more than $6 billion losses annually in global aquaculture (shrimp, salmon & others) due to disease.
QuaraView™ data services will allow users to track measurements over time and input weather, feeding and other variables.
Early disease diagnostics, biosecurity measures, and assigning budgets to mitigation and contingency are effective measures to save millions of dollars.
More than 700,000 people die annually around the world from superbug bacterial infections.
Rapidly sense a life-threatening infection and the need for treatment — critically important for sepsis and other infections.
Will help manage treatment by rapidly sensing the efficacy of treatment.
Will help control the spread of infectious disease that cost lives and billions in health care costs.
Veterinarians or animal owners will be able to quickly determine if their livestock or pet has a harmful bacterial infection.
Will help mitigate suffering and will reduce veterinary costs in the estimated $260 billion annual pet industry.
Approximately 70% of antibiotics in the US are given to livestock for preventative reasons – now they can be given only when a bacterial threat is present, saving millions of dollars and helping the fight against superbugs from the overuse of antibiotics.
Food Processing and Industrial Pipelines:
Will provide real-time sensor data for managing bacterial outbreaks from food-processing equipment to oil pipelines or pharmaceutical manufacturing.
Early detection of a bacterial threat will help to minimize the formationi of harmful biofilms.
Early warning will reduce costly plant shut-downs that can cost millions of dollars and do irreversible reputational damage.
The views presented in this document are for discussion purposes only. Quara Devices Inc. “The Company” is not advocating any of the courses of action presented in it, which are being presented solely to illustrate a range of available options. This analysis is presented on the understanding that, apart from showing this document to those of your officers, employees or advisers who are engaged in reviewing it on your behalf, its contents will not be reproduced, redistributed or passed on, directly or indirectly, by you to any other person or published, in whole or in part, for any purpose without our written permission. This document does not constitute or form part of any offer for purchase, sale or subscription of, or solicitation or invitation of any offer to buy, sell or to subscribe for, any securities nor may it or any part of it be relied on in connection with any contract or commitment whatsoever. If you do not have professional experience in matters relating to investments you should not act or rely on it, and you should return this document. The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. By accepting this document you agree to be bound by the terms of this notice. This document has been prepared from information which is believed at the date of this document to be reliable. Phrases like "expects," "believes,” "anticipates" and similar phrases do not constitute warranties or guarantees of any kind, expressed or implied. The information in this document is subject to change without notice. We undertake no responsibility or obligation to provide you with any additional information or to update the document or to correct any inaccuracies in it that may become apparent. The information in this document must not be used as the basis for any prescribing decisions and may not represent the approved label in all territories. Our affiliate and subsidiary companies retain the right to request the return of this document at any time. The Company’s affiliate and subsidiary companies expressly disclaim any and all liability for representations or warranties, expressed or implied, contained in, or for omissions from, this document or any written or oral communication concerning it or its subject matter.
THE COMPANY HAS NOT COMMENCED ITS PLANNED OFFERING UNDER REGULATION A OF THE SECURITIES ACT. NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED FOR THAT PLANNED OFFERING, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT FILED BY THE COMPANY WITH THE SEC HAS BEEN QUALIFIED BY THE SEC. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND.